ANTENGENE-B (06996) Founder, CEO, Chairman and other management increased their shareholdings.

date
08:19 25/03/2026
avatar
GMT Eight
Deqi Pharmaceuticals-B (06996) announced that the Board of Directors of the Company has been informed by Dr. Mei Jianming, the founder, executive director, CEO and chairman of the Company, that on March 23 and 24, 2026, Dr. Mei, through a controlled entity, purchased a total of 200,000 ordinary shares of the Company in the open market at an average price of approximately $0.512 per share (equivalent to approximately HK$3.99 based on an exchange rate of 7.8), representing approximately 0.029% of the total issued shares (excluding 202,500 treasury shares).
ANTENGENE-B (06996) announces that the Board of Directors has been informed by Dr. Meijianming, the founder, executive director, CEO and chairman of the company, that on March 23 and 24, 2026, Dr. Mei acquired a total of 200,000 ordinary shares of the company through an entity controlled by him in the open market at an average price of approximately $0.512 per share (equivalent to approximately 3.99 Hong Kong dollars calculated at an exchange rate of 7.8), representing approximately 0.029% of the total issued shares (excluding 202,500 treasury shares). Following this purchase, under the Securities and Futures Ordinance (Chapter 571) of Hong Kong, Dr. Mei holds or is deemed to hold a total of 184 million shares, representing approximately 27.158% of the total issued shares (excluding 202,500 treasury shares) as of the date of this announcement. The Board of Directors was further informed by Mr. Long Zhenguo, the executive director and CFO of the company, that on March 23 and 24, 2026, Mr. Long purchased a total of 502,500 shares at an average price of approximately 4.006 Hong Kong dollars per share in the open market, representing approximately 0.074% of the total issued shares (excluding 202,500 treasury shares). Following this purchase, under Part XV of the Securities and Futures Ordinance, Mr. Long holds or is deemed to hold a total of 4,482,500 shares, representing approximately 0.66% of the total issued shares (excluding 202,500 treasury shares) as of the date of this announcement. The Board of Directors was also informed by Mr. Cao Yang, the Vice President and Company Secretary, that on March 23 and 24, 2026, he acquired shares in the open market for a total consideration of 1.042 million Hong Kong dollars. Dr. Mei, Mr. Long, and Mr. Cao have informed that the total consideration paid for the purchase of shares in the open market amounts to a total of 3.853 million Hong Kong dollars. According to Dr. Mei, Mr. Long, and Mr. Cao, these purchases were based on their strong confidence in the long-term investment value, robust research and development capabilities, and continuous innovation capabilities of the Group. They believe the Group is well positioned to advance its pipeline and achieve sustainable long-term growth. Subject to compliance with applicable laws and regulations, they do not rule out the possibility of further increasing their holdings in the company at an appropriate time. The Board of Directors believes that these purchases reflect their strong confidence in the future prospects of the company and their long-term commitment to its development.